

P.E.I. Pharmacare Bulletin

Issue (2019-issue#1)

January 14, 2019

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY

(Effective Date: January 28, 2019)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
brivaracetam	<u>Brivlera</u>	10mg	tablet	02452936	UCB
		25mg	tablet	02452944	UCB
		50mg	tablet	02452952	UCB
		75mg	tablet	02452960	UCB
		100mg	tablet	02452979	UCB
Criteria	For the treatment of partial onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy if the following clinical criteria and conditions are met: 1. Patients are currently receiving two or more antiepileptic drugs (AEDs). 2. Patients are not receiving concurrent therapy with levetiracetam. 3. Patients are those for whom less costly AEDs are ineffective or not clinically appropriate.				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Seniors Drug Program, Nursing Home Drug Program, Catastrophic Drug Program				
elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide	<u>Genvoya</u>	150mg/150mg /200mg/10mg	tablet	02449498	GIL
Criteria	Open benefit - coverage is currently effective				
Program Eligibility	AIDS/HIV Drug Program				